Notice of Results

RNS Number : 2046Z

Shield Therapeutics PLC

13 March 2017

 

Shield Therapeutics plc

("Shield" or the "Group")

Notice of Results

London, UK, 13 March 2017: Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on the development and commercialisation of late-stage pharmaceuticals that address unmet medical needs in secondary care, announces it will report its audited results for the year ended 31 December 2016 on Tuesday 4 April 2017.

CEO, Carl Sterritt, and members of the management team will host a presentation and live conference call for analysts at 9.30am BST on the morning of the results in the Guildhall Room at 85 Gresham Street, London, EC2V 7NQ.

- Ends -

For further information please contact:

Shield Therapeutics plc	[phone]
Carl Sterritt, Chief Executive Officer
Nominated Adviser and Broker Liberum Capital Limited Christopher Britton/Steve Pearce	[phone]
Financial PR Advisor Consilium Strategic Communications	[phone] [e-mail]
Mary-Jane Elliott/Matthew Neal

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until 2034. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com.

 

END

 

 

NORBRGDXUXBBGRG